Techspert

Top 10 most notable expert requests for May 2021

Written by Vivien Tsang, Associate Project Manager, 7 June 2021

Discover the range of experts our customers gained insights from in May to help them make smarter, better informed decisions in our top 10 most notable expert requests! 

 

Top 10 expert requests May 2021

1. Ophthalmology KOLs unlock insights on Europe’s dry eye disease market 

A management consulting firm conducting market research on behalf of a pharmaceutical client needed to evaluate the market potential for a drug to treat dry eye disease in Europe. Thus, they asked us to connect them with prescribing ophthalmology key opinion leaders (KOLs) based in the UK, Germany, Italy, and Spain to gain these insights. 

Using our AI-driven search technology, we found the exact KOLs the customer needed to engage with. This enabled them to gain a better understanding of existing therapeutic practices and develop strategic recommendations to help their pharmaceutical client launch their drug to treat dry eye disease in new markets across Europe. 

The ophthalmology KOLs we connected the customer with included: 

  • An Associate Professor and high-volume surgeon in a Department of Ophthalmology who serves as principal investigator on many clinical trials, has published 100 papers in peer-reviewed journals and treats an average of 1,000 dry eye disease patients a year. 
  • A Professor and senior physician who has authored over 500 peer-reviewed publications, treats an average of 1,500 patients with dry eye disease annually and is affiliated with several societies such as the European Association for Vision and Eye Research (EVER). 

 

2. Senior executives enable consultancy to gauge supply and demand for booming cell therapy market 

The global cell and gene therapy (CGT) market is expected to boom over the next decade. In fact, this market intelligence report forecasts the market to grow from $6.69 billion in 2020 to $17.32 billion in 2025.  

Given the dramatic growth in the market and its potential, pharmaceutical companies are increasingly investing in CGT.  

For instance, a consultancy conducting a study on behalf of a pharmaceutical company needed to gauge supply and demand for cell therapy manufacturing. As such, they asked us to source them industry experts to understand how companies choose outsourcing partners for cell therapy manufacturing. 

Because our AI searches for experts in real-time, we can identify thought leaders in a constantly evolving knowledge landscape working at the forefront of their fields. This ensures our customers connect with today’s experts, not yesterday’s. 

The senior executives the customer engaged with included: 

  • A Director of Cell Therapy Manufacturing experienced in manufacturing over 12 cell therapies and who’s directly involved in the decision-making responsibilities regarding the outsourcing for cell therapy production. 
  • A Senior Vice President of Biologics Cell and Gene Therapy experienced in leading research and clinical cell manufacturing from early-stage product pipelines and is solely responsible for decision-making regarding outsourcing cell therapy production. 

 

3. Experts shed light on unmet needs, drivers, and barriers in testosterone replacement therapy market 

A strategy consultancy supporting a pharmaceutical client needed to understand the drivers and barriers in testosterone replacement therapy (TRT) and identify unmet needs in this market. 

They asked us to connect them with US-based primary care physicians (PCPs), urologists and endocrinologists who treat TRT patients to gauge their interest in a new oral TRT medication. 

With precision and speed at its core, our technology identified the relevant experts for the customer to engage with. Therefore, enabling them to develop a go-to-market strategy for their pharmaceutical client’s new oral TRT medication. 

Some of the experts we sourced for the customer were: 

  • A Professor of Urology who spends 90% of their time in direct patient care, has authored 300 academic papers, is an investigator on five clinical trials and is a regular contributor to national and international conferences and lectures. 
  • A Professor of Urology who specializes in the treatment of men's health problems, spends 75% of their time in direct patient care, is on the editorial board of the Journal of Sexual Medicine and has authored 14 papers on testosterone replacement. 

 

4. Consultancy leverages primary insights to test opportunity of a potential novel skin cancer drug 

A market research firm needed our support for a project in the disease state of advanced cutaneous squamous cell carcinoma (cSCC) – a common type of skin cancer. 

They needed to better understand the advanced cSCC treatment landscape and to test the opportunity of a potential novel drug for advanced cSCC patients. They predominantly wanted to explore perceptions of current available systemic treatments for advanced cSCC, remaining unmet needs, perceptions, and anticipated coverage of a potential novel drug. 

To gain these insights, they asked us to connect them with US-based general medical oncologists and dermato-oncologists.  

We’ve developed a Knowledge Graph which gives us a real-time visualization of the knowledge landscape, enabling us to rapidly identify the thought leaders in any given field and connect them with the businesses who seek their knowledge.  

 techspert.io Knowledge Graph

A subset of our Knowledge Graph depicting the relationships between concepts whereby clusters of nodes represent related diseases, syndromes, and disorders.  

 

Leveraging our Knowledge Graph, which has access to 2.5 billion high-quality expert profiles, we found the right experts for the customer to engage with, such as: 

  • A medical oncologist and Assistant Professor of Medicine experienced in using various immunotherapies to treat advanced cSCC patients, is an active member of the American Society of Clinical Oncology and is listed as a contributing author on 90 academic papers. 
  • A dermato-oncologist and Associate Professor in a Division of Oncology who has conducted clinical research trials for the treatment of patients with advanced cSCC, and is experienced in using various immunotherapies to treat advanced cSCC patients. 

 

5. KOLs and market access experts forge path into systemic sclerosis market 

A healthcare strategy consultancy researching the systemic sclerosis (SSc) market in the UK, Germany and Italy needed to engage with relevant, local KOLs and market access experts in each market to inform strategic recommendations they were developing for their end client. 

The KOLs needed to have participated in clinical trials for SSc, presented on SSc at conferences, or participated in SSc guideline development. 

The market access experts needed to be current or former market access leads in pharmaceutical companies experienced in non-topical dermatologic treatments and rheumatologic treatments. 

Using the knowledge gathered from the expert engagements we facilitated, the customer developed recommendations to expand their client’s SSc portfolio in new markets. 

The experts they connected with included: 

  • A rheumatologist who is also the coordinator of an SSc clinic, has authored 70 scientific publications, presented at SSc World Congress 2020, and has participated in the drafting of regional and national treatment guidelines for SSc. 
  • A Global Market Access Director at a pharmaceutical company with over 20 years of experience in the industry, experienced in market access and pricing for non-topical dermatologic treatments and rheumatologic treatments. 

 

6. Consultancy strengthens market research with KOL insights  

A consulting firm completing a project on non-muscle invasive bladder cancer (NMIBC) needed us to source them KOLs to inform their market research. The KOLs had to be based in the US, France, Germany, and Italy and meet criteria such as: 

  • Have a history of relevant peer-reviewed publications, clinical trial involvement, and/or professional society leadership 
  • Be knowledgeable in disease etiology and frequently mutated genes in NMIBC    
  • Be an expert in the current treatment paradigm, its evolution, and novel therapeutics targeted for early-stage bladder cancer 

Our AI thrives on precision and has been trained to find the most useful data for producing accurate, comprehensive expert profiles. This allows us to find experts with pinpoint accuracy, experts that often can’t be found in traditional panels. 

The NMIBC KOLs the customer gained insights from included: 

  • A urologic surgeon at a cancer center who is the principal investigator for several clinical trials examining new treatment approaches for people with bladder cancer, and author of many book chapters and research articles on genitourinary cancers. 
  • A Professor of Urology and Chief of Urologic Oncology at a medical center who has co/authored 600 scientific papers and is a member of various professional organizations such as the Society of Urologic Oncology. 

 

7. Consultancy leverages insights gained from medical oncologists for market research 

A management consultancy completing market research in the chemo-induced nausea and vomiting (CINV) space needed to engage with medical oncologists to supplement their project. The respondents had to be based in the US, France, Germany, Italy, and Spain, as well as: 

  • Diagnose, treat, and manage CINV patients 
  • Practice in an academic medical center, regional health system, or university hospital 
  • Be a member of an advisory board, have written two major review articles, been involved in clinical trials, authored 10+ papers, and/or be the head of medical oncology 

Based on the above requirements, our technology found the relevant specialists for the customer to engage with, such as: 

  • A Medical oncologist and Head of Medical Oncology at a university hospital who has co/authored 142 publications, is associated with 19 clinical trials, and is a member of the European Organization for Research and Treatment of Cancer. 
  • A Medical oncologist and Associate Professor at an academic medical center who is a member of the European Society for Medical Oncology, has contributed to 47 peer-reviewed publications and involved in four clinical trials. 

 

8. Healthcare practitioners shape online medical education events 

Because of COVID, many companies have turned to online events to keep engaged with their audiences and target markets, including pharmaceutical companies. 

A healthcare and life sciences consultancy working on a project for an end client needed to find out how COVID has affected online events in medical education, and what can be changed to appeal to physicians.  

As such, they needed to engage with various healthcare practitioners (HCPs) such as diabetologists, endocrinologists, obesity specialists, cardiologists, nurses and hepatologists, across a range of countries, such as the UK, Brazil, Japan, Canada, Saudi Arabia, India, China, Germany, and France. 

Unlike traditional panel vendors, our AI isn’t confined to a database of experts. Instead, it trawls through billions of publicly available online data points to identify leading experts. This allows us to connect our customers with experts from all over the world. 

Global coverage map

Since the beginning of the year, we’ve connected our customers with experts across 31 countries! 

 

Some of the HCPs the customer engaged with were: 

  • A Head of Bariatric Surgery who has published 58 scientific papers, has presented at global conferences, is a fellow of an international society for metabolic and bariatric surgery and started attending virtual medical education events before COVID. 
  • A Professor and Director of Interventional Cardiology who’s a member of steering committees for clinical trials, has presented at national and international scientific meetings, and only started attending virtual medical education events because of COVID. 

 

9. KOLs share expertise on clinical and preclinical pipeline and the future of Huntingdon's disease 

A life science consulting firm working on a market research project needed to engage with KOLs to develop a deeper understanding of the clinical and preclinical pipeline and the future of Huntingdon's disease. 

As such, they asked us to source and connect them with EU5 (Italy, Spain, Germany, France, and the UK) and US-based neurologists or psychiatrists with secondary medical specialty in movement disorders or neurodegenerative disease. 

Powered by our Knowledge Graph, we found relevant, precision-matched experts for the customer to engage with, such as: 

  • A neurologist and medical director of a movement disorders center who’s currently involved in 11 clinical trials for Huntington's disease and other neurodegenerative disorders, and who’s co/authored 290 publications. 
  • A neurologist and psychiatrist who is the director of a Huntington’s disease clinic, has co/authored 160 publications, and uses molecular genetic technologies to study basic molecular processes and neurological diseases. 

 

10. Market research on cell and gene therapy manufacturing supplemented by bioproduction experts 

In line with the increasing activity we’ve seen in the market, a strategy consulting firm completing market research on cell and gene therapy manufacturing needed to conduct qualitative interviews with bioproduction experts to inform their project.  

The specialists needed to be US and Europe-based and experienced in cell/gene therapies and the upstream/downstream and fill/finish stages of bioprocessing. 

Our AI-driven approach to sourcing experts enabled the customer to do qualitative interviews with bioproduction experts including: 

  • A Vice President of CMC (chemistry, manufacturing, and control) at a biopharmaceutical company responsible for preclinical development, process development manufacturing and all cell and gene therapy CMC operations. 
  • A Gene Therapy CMC Project Leader with 18 years of experience in R&D and CMC manufacturing who works in all stages of bioprocessing and is currently overseeing product programs for viral vector gene therapies. 

Whether you’re gauging supply and demand for the booming cell therapy market or developing strategic recommendations to help your client expand their portfolio, our AI finds the best experts for you to gain insights from, every time. 

Join us next month for the top 10 most notable expert requests for June 2021! 

Topics: Success Stories